Real-world comparison of cabozantinib versus regorafenib as second-line therapy for advanced hepatocellular carcinoma after first-line immune checkpoint inhibitors: A propensity score–matched analysis.
| Published in: | Journal of Clinical Oncology Vol. 44; pp. 132 - 198 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Published: |
American Society of Clinical Oncology
2026 Supplement 19
|
| Online Access: | View this record in EBSCOhost |